| 产品名称 | ABT 869 - Linifanib |
| 产品货号 | Axon 1638 CAS [796967-16-3] MF C21H18FN5OMW 375.40 Purity: 99% Soluble in DMSO Description A multi-targeted receptor tyrosine kinase (RTK) inhibitor, targeting VEGRFs, PDGFRs, Fms-like tyrosine kinase-3 and c-KIT. In cellular assays ABT869 inhibits RTK phosphorylation (IC50 = 2, 4, and 7 nM for PDGFR-β, KDR, and CSF-1R, respectively) and VEGF-stimulated proliferation (IC50 = 0.2 nM for human endothelial cells) References Certificates Categories Extra info DH Albert et al. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Cancer Ther. 2006, 5, 995-1006. J Zhou et al. ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J. Hematol. Oncol. 2009, 2, 33. AK Ikeda et al. ABT-869 inhibits the proliferation of Ewing Sarcoma cells and suppresses platelet-derived growth factor receptor beta and c-KIT signaling pathways. Mol. Cancer Ther. 2010, 9(3), 653-60. Certificate of Analysis Material Safety Data Sheet Angiogenesis Cell Signaling & Oncology FLT3 VEGFR PDGFR c-KIT RTK class III and IV; EC 2.7.10.1 PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor Chemical name 1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea Parent CAS No. [796967-16-3] Order Size Unit Price Stock 5 mg €85.00 In Stock |
| 产品价格 | 现货询价，电话：010-67529703 |
| 产品规格 | |
| 产品品牌 | axonmedchem |
| 产品概述 | |
| 产品详情 |
ABT 869 - LinifanibAxon 1638 CAS [796967-16-3] MF C21H18FN5O
Description
A multi-targeted receptor tyrosine kinase (RTK) inhibitor, targeting VEGRFs, PDGFRs, Fms-like tyrosine kinase-3 and c-KIT. In cellular assays ABT869 inhibits RTK phosphorylation (IC50 = 2, 4, and 7 nM for PDGFR-β, KDR, and CSF-1R, respectively) and VEGF-stimulated proliferation (IC50 = 0.2 nM for human endothelial cells)
PDGFR, c-KIT and VEGFR tyrosine kinase inhibitor
Chemical name1-(4-(3-amino-1H-indazol-4-yl)phenyl)-3-(2-fluoro-5-methylphenyl)urea Parent CAS No.[796967-16-3] |
| 产品资料 |
